trending Market Intelligence /marketintelligence/en/news-insights/trending/gHon_BPOIkT_OCvAV5UpJA2 content esgSubNav
In This List

Prescient puts cancer drug trial on hold after patient death

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Prescient puts cancer drug trial on hold after patient death

Prescient Therapeutics Ltd. placed the phase 1b breast cancer trial of its lead drug PTX-200 on hold after reporting a fatality.

The trial, which enrolled 29 patients, was evaluating PTX-200 in combination with chemotherapy drug paclitaxel. The Australian company said the patient, suffering from stage 4 metastatic triple negative breast cancer, experienced hepatic or liver failure during treatment with the medication.

The principal investigator of the trial believes the death could be related to PTX-200, paclitaxel or pioglitazone, a diabetes drug.

Prescient said it temporarily paused recruitment to all PTX-200 trials to further investigate the death and notified the U.S. Food and Drug Administration, which put the trial on clinical hold.

The patient death would appear as a blow to the company, given that PTX-200 was scheduled to move into phase 2 study.